INTRODUCTION
The annual worldwide mortality from liver cirrhosis is approximately 800,000 [1] , and there is no available treatment [2] . Excessive tissue repair in chronic liver diseases induced by viral, toxic, immunologic, and metabolic disorders [3] , results in the deposition of scar tissue and the development of cirrhosis [4] . Quiescent hepatic stellate cells (HSC) produce negligible amounts of extracellular matrix proteins (ECM), but after their activation, these cells develop a myofibroblastic phenotype, proliferate and become the main contributors of ECM [5] [6] . This step is required for the development of liver fibrosis and cirrhosis [7] [8] [9] .
The mitogen-activated protein kinase (MAPK) pathway, through the extracellular signal-regulated kinase (ERK1/2), activates RSK [10] [11] [12] [13] [14] , resulting in the phosphorylation of mouse C/EBPb (NP_034013 XP_916631) on Thr217 (Thr266 in human C/EBPb) [5] [10] . The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK [15] , blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 [10] . The RSK phosphoacceptor site in C/EBPb is identical in mouse and human, it is evolutionarily conserved [5] , and essential for survival of activated HSC [10] .
Here we show that activation of RSK and phosphorylation of C/ EBPb on Thr217 in activated HSC is critical for the progression of liver fibrosis. Chronic exposure to the hepatotoxin CCl 4 can induce liver cirrhosis in humans, and it is a classical method of inducing liver injury and fibrosis in mice [10] [16] . We used this model to investigate the role of RSK and phosphorylation of C/EBPb on Thr217 in liver fibrosis. The hepatotoxin CCl 4 induced severe liver fibrosis in C/EBPb +/+ mice but not in mice expressing C/EBPbAla217, a non-phosphorylatable RSK-inhibitory transgene. C/ EBPb-Ala217 was present within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. C/ EBPb +/+ mice with severe liver fibrosis induced by an 8-week CCl 4 treatment, while continuing on CCl 4 , were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl 4 . We found similar activation of RSK and phosphorylation of human C/EBPb (NP_005185) on Thr266 (identical human phosphoacceptor) in activated HSC in the liver of patients with severe liver fibrosis. These data indicate that the RSK-C/EBPb phosphorylation pathway is critical for the development of liver fibrosis, and that inhibition of the RSK pathway is a potential therapeutic strategy for the prevention and treatment of liver cirrhosis.
RESULTS
Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are resistant to hepatotoxin-induced liver fibrosis nonphosphorylatable RSK-inhibitory C/EBPb-Ala217 transgene. This mutation changes the phosphorylatable Thr217 to a nonphosphorylatable Ala217 within the RSK phosphoacceptor site of C/EBPb. These animals are developmentally normal, fertile and have a normal life span [10] , suggesting that the RSKinhibitory transgene is apparently not toxic.
After the thrice-weekly intraperitoneal administration of CCl 4 for 12 weeks, we determined the degree of liver fibrosis in coded samples. This is an extensive chronic exposure for mice and comparable to established severe liver fibrosis in humans [17] . We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR clinical grading system; iii) collagen type 1 immunofluorescence; iv) quantitative Sirius red collagen-binding assay; v) quantitative hydroxyproline collagen content; vi) RT-PCR for collagen type 1 mRNA; vii) RT-PCR for a-smooth muscle actin (a-SMA) mRNA (present in activated HSC); and viii) RT-PCR for transforming growth factor (TGF-b) mRNA (a pro-fibrotic cytokine) [4] [7] [8] .
Liver samples were stained with the classical Mallory's trichrome to identify collagen in the extracellular matrix. The hepatic collagen pattern and content of C/EBPb +/+ (wt) mice treated with CCl 4 for 12 weeks were similar to those of patients with liver cirrhosis ( Figure 1A ) [4] [8] . We graded the coded liver samples with the standard 0 to 4 METAVIR clinical system [18] , and found that after CCl 4 treatment, all C/EBPb +/+ mice had severe liver fibrosis (grade 4; n: 12), while all C/EBPb-Ala217 mice had minimal or no liver fibrosis (grade 0; n: 6; grade 1; n: 6) (P,0.0001) ( Figure 1A ). In agreement with the findings with the Mallory's trichrome, the Sirius red collagen-binding stain also demonstrated decreased liver fibrosis after CCl 4 treatment in C/ EBPb-Ala217 mice ( Figure 1B) . Similarly, confocal scanning microscopy with specific antibodies against collagen type 1 also identify decreased liver fibrosis in C/EBPb-Ala217 mice, compared to C/EBPb +/+ mice, after CCl 4 treatment ( Figure S1 ). Although the intra-and inter-observer variability in the semiquantitative analysis of liver fibrosis was low, we confirmed these findings using quantitative analysis of liver fibrosis.
The quantitative analysis of liver collagen, the major extracellular matrix protein in liver fibrosis [4] , with the Sirius red collagen-binding assay [19] (Figure 1C) , demonstrated that C/ EBPb-Ala217 mice were refractory to the development of liver fibrosis after chronic exposure to the hepatotoxin. The liver [ko] mice received weekly IP injections of CCl 4 or mineral oil (control) for 12 weeks as described in Methods. A. Representative Mallory's trichrome stain for liver fibrosis (in blue; arrowheads). All C/EBPb +/+ (wt) mice (n: 12) developed severe liver fibrosis. The C/EBPb-Ala217 (n: 12; P,0.0001) and C/EBPb 2/2 [ko] (n: 6; P,0.01) mice had either no fibrosis or only minimal liver fibrosis. B. Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBPb +/+ , but not in C/EBPb-Ala 217 or C/EBPb 2/2 [ko], mice. C. Analysis of hepatic collagen content by the Sirius red collagen-binding assay, showed a ,2.5-fold increase in C/EBPb +/+ mice treated with CCl 4 (n: 12), compared to C/EBPb-Ala217 mice treated with CCl 4 (n: 12; P,0.001). C/EBPb 2/2 mice were also refractory to the induction of liver fibrosis by CCl 4 (n: 6; P,0.01). D. Analysis of hepatic collagen content by the hydroxyproline assay, showed a ,2-fold increase in C/EBPb +/+ mice treated with CCl 4 (n: 7), compared to C/EBPb-Ala217 mice treated with CCl 4 (n: 6; P,0.01). C/EBPb 2/2 mice were also refractory to the induction of liver fibrosis by CCl 4 (n: 6; P,0.01). doi:10.1371/journal.pone.0001372.g001 collagen content increased approximately 2.5-fold from baseline in C/EBPb +/+ (wt) mice (P,0.001) while remaining unchanged in C/EBPb-Ala217 mice (NS) ( Figure 1C) . Similarly, chronic administration of CCl 4 increased liver hydroxyproline collagen content in C/EBPb +/+ (wt) mice (P,0.01) while remaining unchanged in C/EBPb-Ala217 mice (NS) ( Figure 1D ).
We have reported that by lacking the essential C/EBPbPhosphoThr217, C/EBPb2/2 HSC are also unable to survive the activation signals [10] . Thus, we postulated that C/EBPb2/2 mice would be refractory to the induction of liver fibrosis. Indeed, C/EBPb 2/2 (ko) mice had a lower fibrotic response than C/ EBPb +/+ mice to the chronic treatment with CCl 4 (P,0.01) (Figure 1 A, B, C and D) .
Further, the expression of the liver fibrogenic indicators such as collagen a 1 type 1 mRNA (newly synthesized collagen) (NM_ 007742 )(P,0.01), a-SMA mRNA (activated HSC) (NM_007392.2) (P,0.05), and TGF-b mRNA (fibrogenic cytokine) (NM_009370.2) (P,0.01), were induced by CCl 4 treatment significantly more in C/ EBPb +/+ mice than in C/EBPb-Ala217 mice as measured by RT-PCR (Figure 2 ). Figure 2 . Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are resistant to hepatotoxin-induced liver fibrogenesis. Mice were treated with CCl 4 or control mineral oil for 12 or 16 weeks and RT-PCR was performed as described in Materials and Methods. A. RT-PCR for collagen a1 type 1 was induced in C/EBPb +/+ [wt] mice treated with CCl 4 for 12 or 16 weeks (P,0.01). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods blocked this increase at week 16 (P,0.05). Collagen a1 type 1 was not increased in livers of C/EBPb-Ala217 mice at 12 or 16 weeks (P,0.01). B. RT-PCR for a-SMA was induced in C/EBPb +/+ [wt] mice treated with CCl 4 for 12 or 16 weeks (P,0.05). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods blocked this increase at week 16 (P,0.05). a-SMA was not increased in livers of C/EBPb-Ala217 mice at 12 or 16 weeks (P,0.05). C. RT-PCR for TGF-b was induced in C/EBPb +/+ [wt] mice treated with CCl 4 for 12 or 16 weeks (P,0.01). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods, blocked this increase at week 16 (P,0.01). TGF-b was not increased in livers of C/EBPb-Ala217 mice at 12 or 16 weeks (P,0.01). doi:10.1371/journal.pone.0001372.g002
In summary, blocking phosphorylation of C/EBPb-Thr217 through the inhibition of RSK activity with the C/EBPb-Ala217 transgene or by C/EBPb gene knock-out decreases the fibrotic response of the liver to chronic injury.
Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are resistant to hepatotoxin-induced liver inflammation Because liver inflammation, at least in part through the activation of macrophages [20] [21] [22] and loss of hepato-trophic factors from HSC and liver endothelial cells [23] [24] is a major contributor to liver injury and liver fibrosis, we assessed the degree of liver injury and inflammation in response to the hepatotoxin. Liver injury was determined by measuring serum alanine aminotransferase (ALT) levels in mice after exposure to the hepatotoxin. Serum ALT is a sensitive and specific indicator of hepatocellular injury in humans and animals, and it is the standard clinical test used by the U.S. Food and Drug Administration to ascertain hepatotoxicity of herbal products and drugs [25] [26] . We found that C/EBPbAla217 mice had less liver injury than C/EBPb +/+ mice after CCl 4 treatment, judging by the ALT serum levels (Table S1) .
Using a microarray assay to assess expression of 66 inflammation genes in the liver of control and transgenic mice, we found that the expression of 21 inflammation genes was decreased, while the expression of other 45 inflammation genes was unchanged in C/EBPb-Ala217 mice after CCl 4 -induced liver injury, when compared to C/EBPb +/+ animals treated with CCl 4 (Table 1 ).
These data suggest that partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/ EBPb-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBPb +/+ mice ( Figure 3A) , may be responsible for the decreased liver injury in C/EBPb-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68+ inflammatory cells to the liver ( Figure 3B ).
Given that CCl 4 is metabolized by the cythocrome-P-450 2E-1(Cyp-2E-1) (ABH07947) to form a free radical hepatotoxic metabolite [27] , we evaluated the possibility that C/EBPb-Ala217 affects Cyp-2E1 expression and/or activity. The Cyp-2E1 mRNA expression was similarly inhibited by CCl 4 in the livers of C/EBPb +/ + and C/EBPb-Ala217 mice ( Figure S2A ). In addition, the Cyp-2E-1 protein expression was also similar in the livers of C/EBPb +/+ and C/EBPb-Ala217 mice after the hepatotoxin treatment ( Figure S2B) . Moreover, the Cyp-2E1 activity as measured in a cell-free system was unaltered by a RSK-inhibitory C/EBPb-Ala217 peptide, even at mM concentrations ( Figure S2C ).
These results indicate that the protective effects of the RSKinhibitory transgene in CCl 4 -induced liver injury and fibrosis are not due to the spurious blockade of the production of a toxic CCl 4 metabolite.
Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are resistant to hepatotoxin-induced HSC activation and proliferation Quiescent HSC produce negligible amounts of ECM, but after their activation, these cells develop a myofibroblastic phenotype, [6] . Because this step is required for the development of liver fibrosis and cirrhosis [7] [8] [9] , we analyzed the activation and proliferation of HSC in the livers of mice chronically exposed to the hepatotoxin.
As expected, chronic CCl 4 administration to C/EBPb +/+ (wt) mice, induced marked activation of HSC, as indicated by the positive immunofluorescence for a-SMA within the scar tissue [5] [6] ( Figure 4A ), and proliferation of HSC, as indicated by the presence of proliferating cell nuclear antigen (PCNA; DNA polymerase d auxiliary protein), an S-phase marker [28] ( Figure 4B ). By contrast, C/EBPb-Ala217 mice were refractory to the induction of HSC activation and proliferation by CCl 4 treatment ( Figure 4A and B). Moreover, chronic CCl 4 treatment induced the apoptotic cascade in HSC in the livers of C/EBPb-Ala217 mice, but not C/EBPb +/+ mice, as determined by the presence of active caspase 3 immunofluorescence ( Figure 4B ). After chronic CCl 4 administration, C/EBPb was phosphorylated on Thr217 in HSC of C/EBPb +/+ mice, but not in C/EBPb-Ala217 mice, as determined by confocal microscopy ( Figure 4A and B), using specific antibodies against this phosphorylated epitope [10] .
Because the mixed cell population of the liver limits the evaluation of signaling cascades in a specific cell type, we studied the fibrogenic pathway in purified HSC. After chronic CCl 4 or control mineral oil administration, we analyzed proteins associated with C/EBPb, immunopurified from HSC, freshly isolated from C/EBPb +/+ and C/EBPb-Ala217 mice. C/EBPb-Ala217 binding to, and blocking, RSK phosphorylation ( Figure 5A ) results in decreased phosphorylation of C/EBPb on Thr217, and presumably, other target survival proteins by activated RSK [5] [10] [11] . The Ac-KAla217VD-CHO or C/EBPb216-253-Ala217 (0.25 nM) peptides inhibited RSK activity in a cell-free system, suggesting a direct effect ( Figure 5B ). The Ac-KThr217VD-CHO wt peptide also inhibited RSK, probably, because it binds to the kinase but cannot be phosphorylated by RSK given its small size ( Figure 5B ).
C/EBPb-Ala217 transgene and unphosphorylated C/EBPb-Thr217 are associated with active caspase 8 and death receptor complex II proteins in HSC Unexpectedly, we found that C/EBPb-Ala217 was present with active caspase 8 in HSC from C/EBPb-Ala217 mice after chronic CCl 4 administration and, to a lesser extent, after mineral oil administration ( Figure 6A ). In contrast, the association between inactive procaspase 8 and C/EBPb-PhosphoThr217 ( Figure 6A ), as well as that between C/EBPb and activated phospho-RSK ( Figure 5A ), increased in HSC of C/EBPb +/+ mice after chronic CCl 4 administration. Reciprocal immunoprecipitation with caspase 8 antibodies confirmed the presence of C/EBPb-Ala217 with active caspase 8 ( Figure 6A ). RSK phosphorylation was inhibited in HSC from C/EBPb-Ala217 mice, indicating that C/EBPbAla217 not only associates with RSK but that it also decreases its phosphorylation and activation ( Figure 5A ). The hypothesis that inhibition of RSK by nonphosphorylatable C/EBPb-Ala217 is critical for caspase 8 activation is supported by the increased caspase 8 activation in HSC from C/EBPb-Ala217 mice after chronic CCl 4 administration ( Figure 6A ).
Next, we studied whether blocking RSK activity results in activation of caspase 8. Activated primary human C/EBPb +/+ HSC were transfected with vectors expressing green fluorescent protein with a control wt RSK (GFP), to facilitate cell sorting, with a dominant negative RSK mutant, or with the RSK-inhibitory dominant negative C/EBPb-Ala217. The HSC were activated on a collagen type 1 matrix, a condition that recapitulates the activation of HSC in vivo [9] , and identified by their expression of GFAP [10] . A phospho-RSK immunoblot was performed on RSK immunoprecipitates from protein lysates of purified HSC in an experiment conducted as described in (Fig. 1) . Phosphorylated RSK (RSKp380) was decreased in HSC isolated from C/EBPb-Ala217 mice. C/EBPb and RSK were similar in the different experimental groups. b-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown. B. RSK activity was determined in a cell-free system as described in Methods. Recombinant RSK was activated with ATP (125 mM) in the presence or absence of AcKThrVD-CHO (200 mM), Ac-KAlaVD-CHO (200 mM), or C/EBPb216-253-Ala217 (0.25 nM) peptides. Staurosporine was used as a control inhibitor (0.01 nM). All C/EBPb peptides inhibited RSK activity to a similar extent as staurosporine (P,0.01). Results from triplicate samples of two independent experiments are shown. C. Primary human C/EBPb +/+ HSC were transfected with vectors (1 mg each) expressing green fluorescent protein with control wt RSK (GFP), a dominant negative RSK mutant, or C/EBPb-Ala217. Transfected HSC were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBPb specific antibodies. C/EBPb-PhosphoThr217 (C/EBPbp217), and caspase 8 immunoblots were performed in C/EBPb immunoprecipitates. Dominant negative RSK or C/EPBb-Ala217 prevented C/EPBb phosphorylation and stimulated the association of unphosphorylated C/EBPb with active caspase 8. b-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown. doi:10.1371/journal.pone.0001372.g005
As expected, C/EBPb-PhosphoThr266 (identical to mouse phosphoacceptor Thr217) was markedly decreased in activated human HSC expressing either the RSK mutant or C/EBPbAla217. Moreover, we found that unphosphorylated C/EBPb was associated active caspase 8 ( Figure 5C ). The RSK phosphoacceptor site in C/EBPb is identical in mouse and human, it is evolutionarily conserved [5] , and essential for HSC survival upon their activation [10] . C/EBPb-Ala266 associated with active caspase 8, in cells expressing the dominant negative RSK ( Figure 5C ), which prevents C/EBPb phosphorylation on Thr266 by RSK. In contrast, in the control cells expressing GFP and RSK wt, C/EBPb was phosphorylated and associated with procaspase 8 ( Figure 5C ), as we reported previously [10] . Reciprocal immunoprecipitation with caspase 8 specific antibodies confirmed the presence of unphosphorylated C/EBPb with active caspase 8 ( Figure 6 B and C). After Figure 6 . C/EBPb-Ala217 associates with active caspase 8 in hepatic stellate cells. A. A caspase 8 immunoblot was performed on C/EBPb immunoprecipitates from protein lysates from samples described in (Fig 5 A) . The association between C/EBPb-Ala217 with active caspase 8 was increased in HSC isolated from C/EBPb-Ala217 mice. Phosphorylated C/EBPb-Thr217 was decreased in HSC from C/EBPb-Ala217 mice treated with CCl 4 . C/EBPb and RSK were similar in the different experimental groups. b-Actin was used as an internal control for the immunoprecipitations. B. Reciprocal caspase 8 immunoprecipitation of experiment described in (A) confirmed the association of C/EBPb-Ala217 with active caspase 8. b-Actin was used as an internal control for the immunoprecipitations. C. Reciprocal caspase 8 immunoprecipitation of experiment described in ( Figure 5C ), confirmed the association of C/EBPb-Ala217 with active caspase 8. b-Actin was used as an internal control for the immunoprecipitations. doi:10.1371/journal.pone.0001372.g006
blocking the RSK-C/EBPb phosphorylation cascade in activated HSC, with either an ERK1/2 inhibitor or a cell permeant AcKAla217VD-CHO peptide, which contains the mutated C/EBPbAla217 phosphoacceptor, unphosphorylated C/EBPb became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP [29] (Figure 7A , B, and C). These associations were identified in C/EBPb, TNFR1, TRAF2, TRADD and RIP immunoprecipitations ( Figure 7 and Figure S3 ). The Ac-KAla217VD-CHO peptide is cell permeant due to its Nterminus acetyl group, as it has been documented for other peptides used as substrate or inhibitors of caspases [30] [31] .
A cell-permeant C/EBPb-Ala217 peptide stimulates active caspase 8 and cell death in collagen type 1-induced activation of cultured HSC
We corroborated the activation of caspase 8 in HSC, under conditions that prevented phosphorylation of C/EBPb, as described above, by demonstrating the association between cytochrome C with Apaf-1 ( Figure 7D ), which reflects a downstream amplification effect of active caspase 8 on mitochondrial apoptotic pathways [32] . The reciprocal analysis could not be performed since Apaf-1 antibodies are not suitable for immuno- precipitation. Moreover, inhibition of the RSK-C/EBPb phosphorylation cascade with the cell permeant C/EBPb-Ala217 peptide, Ac-KAla217VD-CHO induced expression of the apoptosis effector caspase 3 in cultured, activated mouse HSC, but not in primary mouse hepatocytes ( Figure S4 ). These findings suggest a selective induction of apoptotic pathways by C/EBPb-Ala217 peptides in cultured activated HSC but not in cultured primary hepatocytes. This conclusion is supported by the apoptotic changes in activated HSC but not hepatocytes of C/EBPbAla217 transgenic mice treated with CCl 4 , and by the lack of apoptosis of normal quiescent HSC and hepatocytes of C/EBPbAla217 transgenic mice not treated with CCl 4 . In addition, after CCl 4 treatment, hepatocyte injury and hepatic inflammation are decreased in C/EBPb-Ala217 transgenic mice compared to control C/EBPb +/+ mice, arguing for a protective rather than an apoptotic effect on hepatocytes.
Our findings in cell-free, cellular and animal models strongly support the main hypothesis, and suggest a novel, physiological role for unphosphorylated C/EBPb on caspase 8 activation. Indeed, we found that caspase 8 activation is stimulated by C/ EBPb-Ala217 in HSC from C/EBPb-Ala217 mice treated with CCl 4 ( Figure 8A ). In addition, we determined that the peptide enhanced the activity of recombinant caspase 8 in a cell-free system at picomolar concentrations ( Figure 8B ). To our knowledge, the C/EBPb-Ala217 peptides are the first reported compounds to directly enhance caspase 8 activation (G Salvesen, personal communication).
These experiments provided a strong proof-of-principle that RSK activation mediates the signaling required for liver inflammation and liver fibrosis.
A cell-permeant C/EBPb-Ala217 peptide stimulates cell death in hepatotoxin-induced activation of HSC Because in preliminary studies the cell permeant tetrapeptide AcKAla217VD-CHO was effective in inducing apoptosis of cultured activated HSC [10] , we studied whether this peptide would also be effective in inducing apoptosis of activated HSC in a physiologically relevant animal model of liver injury [10] [16] . To activate HSC, we administered a single dose of CCl 4 to C/EBPb +/+ (wt) mice, while control mice received the mineral oil vehicle [16] . Six hours later, animals received an intraperitoneal injection of the cell permeant Ac-KAla217VD-CHO peptide [10] (100 mg) or saline vehicle (100 ml). In preliminary studies, we found that 1-100 mg of peptide dose provided adequate bioavailability (M B, unpublished observations). Animals were sacrificed at 24 h. Acute CCl 4 administration induced both activation and proliferation of HSC (among other hepatic cells), judging by the expression of aSMA and PCNA, as determined by confocal microscopy ( Figure 8C and D) .
HSC activation and proliferation were blocked by treatment with the Ac-KAla217VD-CHO peptide, but not by treatment with saline ( Figure 8C and D) . Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBPb-Ala217 transgenic mice, the Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBPb on Thr217 in HSC activated by the liver injury induced by CCl 4 ( Figure 8C ). Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBPb-A217 transgenic mice, the AcKAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBPb wt HSC as indicated by the presence of active caspase 3 (Figure 8 D) .
A cell-permeant C/EBPb-Ala217 peptide inhibits progression and stimulates regression of hepatotoxin-induced liver fibrosis Activation of stellate cells is responsible for the development of liver fibrosis in chronic liver diseases of all causes [3] [4] [8] , and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis [33] [34] .
Given the effective blocking by the RSK-inhibitory peptide of molecular pathways leading to liver fibrosis in an acute CCl 4 model of liver injury and fibrogenesis, we asked whether these effects would occur in a model of established liver fibrosis due to chronic liver injury, reproducing the disease state of patients with severe liver injury and fibrosis.
Therefore, C/EBPb +/+ mice with severe liver fibrosis, after receiving CCl 4 for 8 weeks, were treated with the RSK inhibitory peptide for an additional 4 or 8 weeks (5 mg IP, three times/week, for week 9, followed by 1 mg IP, three times/week for weeks 10-12 or 10-16), while continuing to induce liver injury and fibrosis with CCl 4 . Treatment of animals with liver fibrosis with the peptide, while continuing to receive CCl 4 , prevented the progression and induced regression of liver fibrosis compared to control mice treated with CCl 4 . At week-12 or week-16, there was a marked regression of liver fibrosis judging by the trichrome stain ( Figure 8E ) and Sirius red staining ( Figure S5 ). All control mice (n: 22) had severe liver fibrosis, while all mice that received the RSK-inhibitory peptide had minimal or no liver fibrosis. We confirmed these findings by quantitative analysis of liver collagen with the Sirius red binding assay (P,0.01) [19] (Figure 8F ). Analysis of hepatic collagen content by the hydroxyproline assay ( Figure 8G ), showed a 2.2-, 3.5-, and 5.3-fold increase in C/ EBPb +/+ mice treated with CCl 4 for 8, 12 and 16 weeks, respectively (n: 8 for 8 weeks; n: 7 for 12 weeks and n: 7 for the 16 weeks), compared to animals treated with the RSK-inhibitory peptide (n: 6 for 12 weeks; n: 8 for 16 weeks; P,0.01).
In agreement with the results observed after CCl 4 treatment in mice expressing the C/EBPb-Ala217 transgene, treatment with the RSK-inhibitory peptide of C/EBPb +/+ mice with severe liver fibrosis induced by CCl 4 , while continuing to receive CCl 4, reduced the following: i) expression of liver fibrogenic indicators such as collagen a 1 type 1 mRNA (P,0.05), a-SMA mRNA (activated HSC) (P,0.05), and TGF-b mRNA (fibrogenic cytokine) (P,0.01) (Figure 2A , B, and C); and ii) recruitment of CD-68+ inflammatory cells to the liver ( Figure 3A ).
Increased expression of active RSK and C/EBPbPhosphoThr266 in activated HSC of human liver fibrosis
The RSK phosphoacceptor site in C/EBPb is identical in mouse and human, it is evolutionarily conserved [5] , and necessary for HSC survival upon their activation [10] . The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK [15] , blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 [10] .
To assess the relevance to human liver fibrosis of the cellular and animal models of liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBPb on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis in four patients with chronic hepatitis C viral infection that resulted in severe liver fibrosis (53617 years) (see Materials and methods). Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis (METAVIR scores of 3 or 4) displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/ EBPb on Thr266 in activated HSC within the fibrous tissue, compared with samples from three control patients (60613 years) as identified by confocal scanning microscopy with specific antibodies against RSK-PhosphoSer380, C/EBPb-PhosphoThr266, and glial fibrillary protein for HSC [10] (Figure 9 A and B). Caspase activation in a cell-free system was determined as described in Methods. The Ac-KAla217VD-CHO peptide enhanced the activation of caspase 8 at picomolar concentrations. Baseline caspase 8 activity was 3.8 U (100%). Results from triplicate samples of three independent experiments are shown (P,0.01 for the AcKAla217VD-CHO peptide). C. Animals received a single injection of CCl 4 or mineral oil as described in Methods. a-SMA (red) and C/EBPbPhosphoThr217 (green) were identified as described in Materials and methods. Treatment with the cell permeant Ac-KAla217VD-CHO peptide blocked the expression of a-SMA and C/EBPb-PhosphoThr217. D. PCNA (red) and active caspase 3 (green) were identified as described in Materials and methods. Treatment with the Ac-KAla217VD-CHO peptide blocked the expression of PCNA and induced active caspase 3. E. C/EBPb +/+ (wt) mice with severe liver fibrosis after treatment with CCl 4 for 8 weeks, while continuing on CCl 4 , received the RSK inhibitory peptide (5 mg IP, three times/ week, for week 9 followed by 1 mg IP, three times/week for weeks 10-12 or 10-16). These are representative Mallory's trichrome stain for liver fibrosis (in blue). All control mice (n: 8 at 8-weeks; n: 8 at 12-weeks; and n: 8 at 16-weeks) developed severe liver fibrosis, while mice receiving the RSK-inbitory peptide (n: 8 at 12-weeks; and n: 8 at 16-weeks) had no fibrosis or only minimal liver fibrosis (P,0.01). F. Analysis of hepatic collagen content by the Sirius red collagen-binding assay showed a ,2.5 to 3-fold increase in C/EBPb +/+ mice treated with CCl 4 (n: 8 for 8 weeks; n: 8 for 12 weeks and n: 8 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for 16 weeks; P,0.01). G. Analysis of hepatic collagen content by the hydroxyproline assay, showed a 2.2-, 3.5-and 5.3-fold increase in C/EBPb +/+ mice treated with CCl 4 , respectively (n: 8 for 8 weeks; n: 7 for 12 weeks and n: 7 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for 16 weeks; P,0.01). doi:10.1371/journal.pone.0001372.g008
Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cellfree, cellular and animal models that RSK activation and its phosphorylation of C/EBPb in activated HSC may be important in the development of human liver fibrosis.
DISCUSSION
Activation of HSC is responsible for the development of liver fibrosis in chronic liver diseases of all causes [3] [4] [8] , and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis [33] [34] .
In this study we show that activation of RSK and phosphorylation of C/EBPb on Thr217 in activated HSC is critical for the progression of liver fibrosis. We used the classical CCl 4 -induced liver injury and fibrosis model in mice [10] [16], primary mouse and human HSC [10] , and cell-free systems to investigate the role of RSK and phosphorylation of C/EBPb on Thr217 in the activation of HSC and liver fibrosis. It would be important to determine whether RSK and phosphorylation of C/EBPb are also critical in other animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury and genetic iron overload [3] . Any one of these studies will require as extensive an analysis as that performed with the CCl 4 model of liver fibrosis.
We found that mice expressing the RSK-inhibitory C/EBPbAla217 transgene were refractory to the induction of HSC activation and proliferation by CCl 4 treatment. After chronic CCl 4 administration, C/EBPb was phosphorylated on Thr217 in HSC of C/EBPb +/+ mice, but not of C/EBPb-Ala217 mice. C/ EBPb-Ala217 binding to, and blocking, RSK phosphorylation results in decreased phosphorylation of C/EBPb on Thr217, and presumably, other target survival proteins by activated RSK. Moreover, chronic CCl 4 treatment induced the apoptotic cascade in HSC in the livers of C/EBPb-Ala217 mice, but not C/EBPb +/+ mice, as determined by the presence of active caspase 8 and 3.
C/EBPb-Ala217 was present within the death receptor complex II, with active caspase 8, and was linked to apoptosis of activated HSC, freshly isolated from transgenic mice. After blocking the RSK-C/EBPb phosphorylation cascade in activated human HSC in culture, with either an ERK1/2 inhibitor or a cell permeant RSK-inhibitory peptide, Ac-KAla217VD-CHO, unphosphorylated C/EBPb became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP [29] . The combined results suggest a functional link between inactive RSK and the active caspase 8 complex II. Further, inactive RSK and active caspase 8 are co-immunoprecipitated with C/EBPb-Ala217 or unphosphorylated C/EBPb, suggesting also a physical link. However, identification of a putative RSK/caspase 8 complex would require crystallographic analysis.
In support of our proposed role of unphosphorylated and phosphorylated C/EBPb-Thr217 on the modulation of HSC survival following their activation by liver injury, expression of the dominant positive phosphorylation mimic C/EBPb-Glu217 [5] enhances survival of cultured progenitor neuronal cells [35] while C/EBPb 2/2 macrophages display defective bacterial killing and tumor cytotoxicity [36] . A corollary of our study is that mice expressing the C/EBPb-Glu217 transgene would be more susceptible to HSC activation and liver fibrosis induced by liver injury and inflammation. Indeed, this seems to be the case in preliminary studies with these novel transgenic mice (M.B, unpublished observations).
Although the association between C/EBPb-PhosphoThr217 and inactive procaspase 8 is linked to the inhibition of active caspase 8 [10] , the precise molecular mechanisms by which phosphorylated C/EBPb prevents liver injury-induced HSC apoptosis have not been characterized yet. Phosphorylated C/ EBPb could induce the inhibition of pro-apoptotic proteins, such as p53 [37] or the activation of survival proteins, such as MnSOD [38] , or FLIP [29] . Alternatively, granzyme B rather than caspase 8 could be the major target of phosphorylated C/EBPb-Thr217, as we suggested previously for HSC apoptosis/survival [10] .
The hepatotoxin CCl 4 induced severe liver fibrosis in C/ EBPb +/+ mice but not in mice expressing C/EBPb-Ala217, a nonphosphorylatable RSK-inhibitory transgene as detected by morphological, semi quantitative and quantitative assays. Blocking phosphorylation of C/EBPb-Thr217 through the inhibition of RSK activity with the C/EBPb-Ala217 transgene or by C/EBPb gene knock-out decreases the fibrotic response of the liver to chronic injury. These findings indicate that the RSK phosphoacceptor site in C/EBPb, which is identical in mouse and human [5] , is essential for HSC survival upon their activation in chronic liver injury in mice. Further, the decreased fibrotic response of the liver to the hepatotoxin in C/EBPb 2/2 mice suggests that the critical target of RSK in activated HSC is C/EBPb-Thr217 rather than other RSK phosphoacceptors in c-Fos, CREB, CBP or other proteins [10] [11] [12] [13] [14] .
Because liver inflammation induces liver injury and liver fibrosis [34] we assessed the degree of liver injury and the inflammatory response to the hepatotoxin. We found decreased liver injury and inflammation in response to CCl 4 treatment in mice expressing the C/EBPb-Ala217 transgene. Our data suggest that in addition to increased HSC apoptosis, partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/EBPb-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBPb +/+ mice, may be responsible for the decreased liver injury in C/EBPb-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68+ inflammatory cells to the liver. Our results are congruent with the proposed role of macrophages as a major contributor to liver injury and liver fibrosis [20] [22] .
Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBPb-Ala217 transgenic mice, the cell permeant Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBPb on Thr217 in HSC activated by the liver injury induced by CCl 4 . Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBPb-A217 transgenic mice, the Ac-KAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBPb +/+ HSC as indicated by the presence of active caspase 8 and 3.
C/EBPb +/+ mice with severe liver fibrosis induced by an 8-week CCl 4 treatment, while continuing on CCl 4 , were treated with the cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulated apoptosis of HSC and blocked active fibrogenesis, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl 4 . Because the resulting activation of HSC and liver fibrosis is similar in any type of chronic liver injury, these results suggest that the inhibition of both RSK and its phosphorylation of C/EBPb may be effective in preventing/ regressing liver fibrosis in animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury, and genetic iron overload [3] .
To assess the relevance of the cellular and animal models of liver fibrosis to human liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBPb on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis. Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/EBPb on Thr266 in activated HSC within the fibrous tissue, compared with samples from control patients. Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cell-free, cellular and animal models implicating RSK activation and its phosphorylation of C/EBPb in activated HSC in the development of human liver fibrosis.
Clinical Implications
Our data indicate that the RSK-C/EBPb phosphorylation pathway in HSC is activated in severe human liver fibrosis, and that it is critical for the progression of liver injury to severe liver fibrosis and cirrhosis in an animal model. This study suggest that blocking RSK activity inhibits fibrogenesis directly by inducing HSC apoptosis, and indirectly, by reducing liver injury and inflammation. There is no available treatment for liver fibrosis. We speculate that these findings may facilitate the development of small molecules potentially useful in the prevention and treatment of liver fibrosis.
Both regression of liver fibrosis as well as lack of progression of liver fibrosis, in spite of continued liver injury, as we clearly documented in our study, are considered important clinical targets for patients with chronic liver disease and liver fibrosis [34] . Finally, blocking the progression of liver fibrosis would decrease development of primary liver cancer in these patients since the majority of hepatocellular carcinomas arise in cirrhotic livers [39] .
MATERIAL AND METHODS

Construction of C/EBPb-Ala217 mice
The Animal Protocol was approved by the VA Healthcare Center's Veterinarian Medical Unit. Transgenic mice expressing C/EBPbAla217, a dominant negative, nonphosphorylatable mutation of the C/EBPb-Thr217 phosphoacceptor, were generated as described previously [10] and back-crossed to the parental wild-type inbreed FVB mice for .4 generations. The mouse C/EBPb cDNA was amplified by PCR to mutate Thr217. The primers used to mutate Thr217 to Ala217 were S 59-GCC AAG GCC AAG AAG GCG GTG GAC AAG CTG AGC -39and AS 59-GCT CAG CTT GTC CAC CGC CTT CTT GGC CTT GGC -39. C/EBPb was removed from pEVRF0 with Apa I and Nhe I and cloned into pHM6 vector (Boehringer-Mannheim, cat. # 1814664) in order to add an RSV promoter upstream to the C/EBPb start site. C/EBPb was removed from this new construct with Bsa I and Bsp. The 982 bp insert was cloned into mammalian vector pOP13CAT (Stratagene) from which the CAT portion had been previously removed. DNA for pronuclear injection was purified over a CsCl gradient and digested with Ssp I and EclHK I. The 3.6 Kb fragment was separated on gel electrophoresis on a 0.8% gel with no Ethidium Bromide. The appropriate band was removed and electro eluted from the gel using the Elutrap apparatus from Schleicher & Schuell. The eluted DNA was purified with a Qiagen-20 column, precipitated with isopropanol and dissolved in 7.5 mM TRIS pH 7.4, 0.15 mM EDTA. All solutions were prepared with tissue grade water, endotoxin tested (Gibco). Finally the DNA was dialyzed and injected into fertilized ova at a concentration of 1.8 mg/ml, at the Transgenic Mouse Core Facilities, University of California, San Diego. The presence of the rsv gene was used to identify these transgenic mice by PCR, and 3 positive mice resulted. The primer sequences for the RSV PCR were custom designed (RSV.2271 TAGGGTGTGTTTAGGCGAAA sense and RSV.2510 TCTG-TTGCCTTCCTAATAAG antisense). The PCR reagents were all from Qiagen. Transgene-bearing founder mice were mated with FVB mice. All founder mice produced viable offspring. This line was bred by mating transgene-positive mice with wild-type FVB and backcrossed to FVB for at least four generations.
Animal Procedures
In the chronic exposure to the hepatotoxin, C/EBPb 4 or mineral oil (50 ml) weekly (for up to 16 weeks), but after 8 weeks, animals received either saline (control) or the cell permeant Ac-KAla217VD-CHO (American Peptide) [10] (5 mg IP, three times/week, for week 9, followed by 1 mg IP, three times/week for weeks 10-12 or 10-16) while continuing to induce liver injury and fibrosis with CCl 4 . In the chronic experiments, animals were sacrificed 24 hr after the last CCl 4 
injection
In the acute exposure to the hepatotoxin, animals received the cell permeant Ac-KAla217VD-CHO [10] (100 mg intraperitoneally) at 18 hr and animals were sacrificed at 24 hr [41] .
Cell cultures
Adult C/EBPb +/+ and C/EBPb-Ala217 transgenic mice were used for the isolation of hepatic stellate cells as described [5] [10] . Stellate cells were prepared, by in situ perfusion and single-step density Nycodenz gradient (Accurate Chemical & Scientific Corp., Westbury, New York), as described previously [6] . Stellate cells were identified by their typical autofluorescence at 328nm excitation wavelength, staining of lipid droplets by oil red, and immunohistochemistry with a monoclonal antibody against desmin. Greater than 95% of the isolated cells were stellate cells.
Primary mouse stellate cells freshly isolated from C/EBPb +/+ mice and activated by collagen type 1 matrix [6] , were transfected with vectors expressing RSK wild type, a catalytically inactive, dominant negative RSK mutant, or C/EBPb-Ala217 together with GFP [10] . Transfected stellate cells were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBPb specific antibodies. In other experiments, stellate cells were incubated for 24 hr with an ERK1/2 inhibitor (Calbiochem 328006) (10 mM), or the KAVD peptide (200 mM).
Microscopy
Fluorescent labels were observed using antibodies against C/ EBPb, RSKPhosphoSer380, a-SMA, PCNA (Santa Cruz Biotechnology, Santa Cruz, California), active caspase 3 (PharMingen, San Diego, California) or C/EBPb-PhosphoThr217 [10] 
Liver Fibrosis
We determined the degree of liver fibrosis in coded samples. We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR grading system [18] ; iii) collagen type 1 immunofluorescence ; iv) quantitative Sirius red collagen-binding assay as described [19] ; v) quantitative hydroxyproline collagen content as described [43] RT-PCR for collagen type 1; vii) RT-PCR for a-smooth muscle actin (present in activated HSC); and viii) RT-PCR for transforming growth factor-b (a pro-fibrotic cytokine) [4] [7] [8] .
For measuring hydroxyproline, the liver was excised and a portion was removed and weighed. Hydrolysis of 10 mg tissue/1ml of 6 M HCl was performed at 120uC in a pressure vessel for 4 hr. Samples were dried overnight in a vacuum desiccator, diluted to fall into the assay sensitivity range and internal standards were prepared. The chloramine-T reagent was prepared and 1 ml was added to each sample. The samples were incubated for 20 minutes. One ml of aldehyde-perchloric acid reagent was added to each sample and incubated at 60uC for 15 minutes. Samples were cooled and absorbance was read at 550nm for samples and standards. Concentrations were determined from the standard curve.
RT-PCR Analysis
We isolated total RNA from control and experimental liver samples using Trizol (Invitrogen). Samples were treated with DNase using Turbo DNA-free (Ambion) and precipitated with chloroform as per manufacturer's protocol. cDNA synthesis was performed using 250 ng of total RNA with the AffinityScript Reverse Transcriptase (Stratagene). Specific sets of primers were utilized for each RT-PCR amplification for collagen a1 type 1, a-SMA and TGF-b, as described by the manufacturer (SuperArray, Frederick, MD).
Liver Inflammation Genes
The liver expression of 86 inflammation genes was determined by using the RT 2 Quantitative Real-Time PCR Array as described by the manufacturer (SuperArray, Frederick, MD). Control and experimental liver samples were analyzed together with internal control samples for the RNA purification and amplification steps, as well as for housekeeping genes (b glucuronidase, hypoxanthine guanine phosphoribosyl transferase 1, heat shock protein1b, glyceraldehyde-3-phosphate dehydrogenase, and b-actin), using the BioRad iQ5 real-time PCR detection system (BioRad, Hercules, CA). Isolation of total RNA, treatment with DNase, precipitation with chloroform, and cDNA synthesis was performed using 1 mg of total RNA as described for RT-PCR following the manufacturer's recommendations.
Cyp-2E1 Expression and Activity
Cyp-2E1 mRNA was measured by RT-PCR in control and experimental liver samples as described above for RT-PCR. Cyp-2E1 protein in liver samples was detected by western blot, following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against Cyp-2E1 (Santa Cruz Biotechnology) as described below.
Cyp-2E1 activity was assessed in a cell-free system, using a recombinant Cyp-2E1 and a specific substrate [44] . Inhibition of Cyp-2E1 activity was achieved using diethyldithiocarbamate (Sigma-Aldrich). We evaluated the effects of the RSK-inhibitory Ac-KAla217VD-CHO peptide (American Peptide) on Cyp-2E1 activity as described per manufacturer (Invitrogen). The standard curve was prepared using dilutions of the fluorescent standard. Master-mix containing the P450 baculosomes reagent, regeneration system, and reaction buffer were added to the designated well of the reaction plate. The plate was incubated for 20 minutes at room temperature to allow the compounds to interact with the Cyp-2E1 in the absence of enzyme turnover. The reaction plate was pre-read at this point to measure any auto-fluorescence. The reaction was initiated with the addition of the reaction mixture containing substrate and NADP. The plate was incubated for 30 minutes, and the fluorescence was measured at 400 and 460 nm. Data analysis was performed as suggested by the manufacturer.
Immunoprecipitation and Immunoblots
Pre-cleared stellate cell lysates were incubated for 2 h with purified C/EBPb, RSK, TRADD or caspase 8 antibodies followed by the addition of A/G+ agarose (Santa Cruz Biotechnology) for 12 h. The immunoprecipitation reactions each contained 500 mg of total protein and 2 mg antibody (or purified IgG pre-immune serum as negative control). Immunoprecipitates were washed 3 times in 500 ml cell lysis buffer [45] and resolved by SDS-PAGE, and C/ EBPb, RSK, RSKp380, TNFR-1, TRADD, RIP, TRAF-2, b-actin and caspase 8 detected by western blot [41] [46] [47] , following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against C/EBPb (C-19; aa 258-276), RSK, RSKp380, TRADD, RIP, b-actin (Santa Cruz Biotechnology), procaspase 8 (PharMingen) and C/EBPb-PhosphoThr217 [10] . Negative samples were performed omitting the first antibody.
Caspase Activity
Purified synthetic N-acetyl, C-aldehyde KAVD tetrapeptide (American Peptide Company, Sunnyvale, California) were assayed for their ability to enhance the activity of purified human recombinant caspase 8 (catalogue # 201-041-C005) (Alexis Biochemicals). The sequence of caspase 8 includes S217 through D479 cloned into an expression vector containing a 21 amino acid linker at the N-terminus. Thus, the prodomain (first 220 amino acids) is essentially missing. The fragment is cleaved at D385 and the active caspase 8 is essentially identical to that identified in apoptotic cells [48] . Caspase 8 activity was also measured in stellate cell lysates, using recombinant caspase 8 as a standard for activity. Caspase activity was determined by the release of the pnitroanaline colorimetric (Alexis Biochemicals, San Diego, California) substrate for caspase 8 (catalogue # 260-045) within the linear part of the kinetic assay [49] [50] . Active caspase 3 was determined with specific antibodies (PharMingen).
RSK Activity
RSK activity was measured by the QTL Lightspeed assay (QTL Biosystems; Santa Fe, New Mexico) using purified recombinant RSK-2 (4,333 U/mg) (Upstate, New York), and staurosporine (0.01 nM) as a control inhibitor. RSK activity was measured in the presence or absence of Ac-KThr217VD-CHO (200 mM), AcKAla217VD-CHO (200 mM), or C/EBPb216-253-Ala217 (0.25 nM) peptides.
Human Livers
We obtained anonymous, de-identified liver samples from 4 patients with chronic hepatitis C viral infection and severe liver fibrosis (Metavir scores of 3 or 4) (53617 years) and from 3 control subjects without liver disease (60613 years) (NDRI). The protocol was approved by the University of California, San Diego Human Protection Program.
Statistical Analysis
Results are expressed as mean (6SD). Either the Student-t or the Wilcoxon Mann-Whitney tests were used to evaluate the differences of the means between groups for parametric and non-parametric populations, respectively, with a P value of ,0.05 as significant. 4 . Thirty hours after a single intraperitoneal dose of CCl 4 C/ EBPb+/+ (n: 9) and C/EBPb2/2 (n: 9) mice had higher serum alanine aminotransferase (ALT) levels than C/EBPb-Ala217 mice (n: 9) (P,0.005 ). Results are representative of three independent experiments. Found at: doi:10.1371/journal.pone.0001372.s001 (0.02 MB DOC) Figure S1 Transgenic C/EBPb-Ala217 and C/EBPb+/+ mice have similar Cyp-2E1 expression in the liver. Mice were treated with CCl 4 or control mineral oil for 24 or 72 hr as described in Materials and methods. A. Liver Cyp-2E1 RNA as determined by RT-PCR was comparable at baseline and after CCl 4 treatment in C/EBPb +/+ [wt] and C/EBPb-Ala217 mice (NS). B. Liver Cyp-2E1 protein as determined by western blot was comparable at baseline and after CCl 4 , treatment in C/EBPb +/+ [wt] and C/ EBPb-Ala217 mice (NS). C. Cyp-2E1 activity as determined in a cell free system using a recombinant Cyp-2E1 protein was comparable in the absence or presence of the RSK-inhibitory Ac-KAVD-CHO peptide (1-1000 ng/ml). Values are expressed as percentage of control Cyp-2E1 activity (open bars) (NS). A specific Cyp-2E1 inhibitor was used as a positive control (closed bar). Found at: doi:10.1371/journal.pone.0001372.s002 (0.66 MB TIF) Figure S2 The association of C/EBPb with active caspase 8, TNFR1, TRAF2, TRADD and RIP is induced by inhibiting RSK in HSC. A Reciprocal TRADD immunoprecipitation of experiment described in (7A) confirmed the association of unphosphorylated C/EBPb with active caspase 8. b -Actin was used as an internal control for the immunoprecipitations. B. Reciprocal TNFR1 immunoprecipitation of experiment described in (Fig. 7B) confirmed the association of unphosphorylated C/EBPb with TNFR1. b-Actin was used as an internal control for the immunoprecipitations. C. Reciprocal TRAF2 immunoprecipitation of experiment described in (Fig. 7C ) confirmed the association of unphosphorylated C/EBPb with TRAF2. b-Actin was used as an internal control for the immunoprecipitations. Figure S4 The RSK-inhibitory peptide blocks liver fibrosis induced by CCl 4 . Mice were from the experiment described in (Fig 8E and F) . Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBPb +/+ treated with CCl 4 but not in animals receiving the RSK-inbitory peptide. Found at: doi:10.1371/journal.pone.0001372.s005 (0.18 MB TIF)
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